drugset / Trial / NCT04348461
BAttLe Against COVID-19 Using MesenchYmal Stromal Cells
Phase 2
Suspended
100 enrolled
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Clinica Universidad de Navarra, Universidad de Navarra · collabHospital General Universitario Gregorio Marañon · collabHospital General Universitario de Alicante · collabHospital Universitario Virgen de la Arrixaca · collabInstituto de Investigación Sanitaria y Biomédica de Alicante · collabUniversity of Salamanca · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The investigational medicinal product consists of expanded allogeneic mesenchymal stromal cells derived from adipose tissue and administered intravenously. The objective of this project is to evaluate the safety and efficacy of the administration of expanded allogeneic adipose tissue adult mesenchymal stem cells, in patients infected with SARS-COV-2 with COVID-19 type complications.
Timeline
- Start
- 2020-05-06
- Primary completion
- 2020-09-15
- Completion
- 2021-09-30
Outcome
Outcome not reported
Stopped (Business): “lack of financial support”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Allogeneic and expanded adipose tissue-derived mesenchymal stromal cells | Cell therapy | 1.5 cells/kg | Intravenous |